GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are contraindicated during breastfeeding per UK Summary of Product Characteristics No weight loss injection currently has regulatory approval for use whilst breastfeeding in the UK Transfer into breast milk and effects on nursing infants remain unknown due to absence of human studies Appetite suppression from these medications may compromise maternal nutrition needed for adequate milk production Safe alternatives include gradual dietary modification, regular physical activity, and NHS weight management programmes Women should defer weight loss medications until breastfeeding is completed and seek GP advice for postpartum weight concerns Table of Contents Weight Loss Injections and Breastfeeding: Key Safety Considerations Types of Weight Loss Injections and Their Use During Lactation Potential Risks to Breastfed Infants Alternative Approaches to Postpartum Weight Management When to Seek Medical Advice About Weight Loss While Breastfeeding Scientific References Frequently Asked Questions Weight Loss Injections and Breastfeeding: Key Safety Considerations Weight loss injections, particularly GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda), have become increasingly popular for weight management
J BiolChem 1952;197:84350
Usually, 1000 mcg (1 mg) is given, but it might be adjusted for each person
This guarantee shows confidence in product quality and gives researchers confidence when introducing new compounds into their protocols
You should also mention any known B12 deficiency, fatigue, numbness, tingling, digestive conditions, or dietary restrictions
The mixing syringe (3 mL with 18-22G blunt tip) is used once to transfer BAC water into the peptide vial
